Wockhardt currently markets 15 products in the US, 10 of them launched during 2006.
Wockhardt is one of the few companies with end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile APIs (active pharmaceutical ingredients), the dosage forms and marketing them through a wholly-owned subsidiary in the US, enabling the company to capture maximum value.
Wockhardt Limited is a technology-driven pharmaceutical and biotechnology company with an active multi-disciplinary research programme employing 400 scientists. Its new drug discovery programme has yielded several promising molecules, one of which is now in Phase II human clinical trials. The US and European Union contribute to more than half of Wockhardt's sales.
